FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

被引：0

作者：

Konecny, Gottfried ^{[1
]}

Hendrickson, Andrea Wahner ^{[2
]}

Winterhoff, Boris ^{[3
]}

Chander, Cinthiya ^{[1
]}

Bilic, Sanela ^{[4
]}

Davenport, Simon ^{[5
]}

Chung, Adrine ^{[6
]}

Miller, Lei-Lani ^{[6
]}

Press, Michael ^{[5
]}

Letrent, Stephen ^{[7
]}

Slamon, Dennis ^{[8
]}

机构：

[1] UCLA, Obstet & Gynecol, Los Angeles, CA USA

[2] Mayo Clin, 200 First St Sw, Rochester, MN USA

[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA

[4] Vanadro, Pharmacol, Urbandale, IA USA

[5] Univ Southern Calif, Dept Pathol, Los Angeles, CA USA

[6] Translat Res Oncol US, Clin Operat, Los Angeles, CA USA

[7] TORL Biotherapeut, Clin Dev, Culver City, CA USA

[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PR062

引用

页码：A67 / A67

页数：1

共 50 条

[31] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
Zhang, Li
Ma, Yuxiang
Zhao, Yuanyuan
Fang, Wenfeng
Zhao, Hongyun
Huang, Yan
Yang, Yunpeng
Chen, Likun
Hou, Xue
Zou, Wen
Ding, Muran
Yu, Jing
Zhang, Suoyu
Wang, Junxian
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin Sebastian
Zhu, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer
Kantoff, P.
Petrylak, D. P.
Pomerantz, M.
Israel, R. J.
Olson, W. C.
Ramakrishna, T.
Morris, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[33] First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
Sung-Bae Kim
Funda Meric-Bernstam
Aparna Kalyan
Aleksei Babich
Rong Liu
Takahiko Tanigawa
Anette Sommer
Motonobu Osada
Frank Reetz
Dirk Laurent
Sabine Wittemer-Rump
Jordan Berlin
Targeted Oncology, 2019, 14 : 591 - 601
[34] BNT211: a Phase 1 Study to determine the Safety and Efficacy of CLDN6 CAR T Cells and CARVAC-mediated in vivo Expansion in Patients with CLDN6-positive advanced solid Tumors
Haanen, J. B.
Mackensen, A.
Koenecke, C.
Alsdorf, W.
Wagner-Drouet, E.
Heudobler, D.
Borchmann, P.
Klobuch, S.
Smit, E.
Bokemeyer, C.
Desuki, A.
Luke, F.
Wiegert, E.
Schulz-Eying, C.
Rengstl, B.
Preussner, L.
Tureci, O.
Sahin, U.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 43 - 44
[35] EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors
Aggarwal, Charu
Azzoli, Christopher G.
Spira, Alexander I.
Solomon, Benjamin J.
Le, Xiuning
Rolfo, Christian
Planchard, David
Felip, Enriqueta
Wu, Yi-Long
Ahn, Myung-Ju
Seiwert, Tanguy Y.
Goto, Koichi
Azaro, Analia
Lissa, Delphine
Hamid, Oday
McGrath, Lara
Maudsley, Rhiannon
Arnaldez, Fernanda I.
Grenga, Italia
Massarelli, Erminia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
Maris, Michael
Salles, Gilles
Kim, Won Seog
Kim, Tae Min
Lyons, Roger M.
Arellano, Martha
Karmali, Reem
Schiller, Gary
Cull, Elizabeth
Abboud, Camille N.
Batlevi, Connie
Kagiampakis, Ioannis
Rebelatto, Marlon C.
Lee, Young
Kirby, Lyndon C.
Wang, Fujun
Bothos, John
Townsley, Danielle M.
Fathi, Amir T.
Ribrag, Vincent
TARGETED ONCOLOGY, 2024, 19 (03) : 321 - 332
[37] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech
Natasha Woodward
Nancy Chan
Joanne Mortimer
Louie Naumovski
Silpa Nuthalapati
Bo Tong
Fang Jiang
Peter Ansell
Christine K. Ratajczak
Jasgit Sachdev
Investigational New Drugs, 2020, 38 : 1815 - 1825
[38] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Lemech, Charlotte
Woodward, Natasha
Chan, Nancy
Mortimer, Joanne
Naumovski, Louie
Nuthalapati, Silpa
Tong, Bo
Jiang, Fang
Ansell, Peter
Ratajczak, Christine K.
Sachdev, Jasgit
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
[39] Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Shapira-Frommer, R.
Sudo, K.
Harano, K.
Mileshkin, L.
Perets, R.
Song, M.
Cohen, J.
Huang, Y-F.
Ambrose, H.
Brier, T.
Dosani, A.
Fraenkel, P. G.
Kmieciak, A.
Mitchell, P.
Myers, C.
Wang, J.
Odegbami, R. I.
Sykes, A.
Turner, S.
Meric-Bernstam, F.
ANNALS OF ONCOLOGY, 2024, 35 : S572 - S573
[40] First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
Wang, Yakun
Gong, Jifang
Lin, Rongbo
Zhao, Shen
Wang, Jufeng
Wang, Qianli
Zhang, Yanqiao
Su, Dan
Zhang, Jingdong
Dong, Qian
Lin, Ling
Tian, Wen
Chen, Ying
Yang, Yang
Zhang, Xueyuan
Wan, Xuechao
Gao, Jinfeng
An, Na
Jansen, Valerie Malyvanh
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →